AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT

Rhea-AI Summary

Aimei Health Technology (Nasdaq: AFJK) received a Nasdaq notice on April 17, 2026 for late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

The Annual Report was due March 31, 2026 and the company filed a Form 12b-25 on April 1, 2026. Nasdaq gave a 60-calendar-day cure period to file or submit a compliance plan; if accepted, AFJK may have up to 180 days from the due date to regain compliance. The notice does not immediately affect listing or trading. The company is working to complete and file the Annual Report and expects to regain compliance.

Positive

• Listing remains active with no immediate trading suspension
• 60-day cure period to file the annual report or submit a plan
• Up to 180 days to regain compliance if Nasdaq accepts a plan

Negative

• Annual Report on Form 10-K was late; due March 31, 2026
• Filed a Form 12b-25 notification on April 1, 2026
• Risk of delisting if compliance is not timely restored

News Market Reaction – AFJK

+1.42%

3 alerts

+1.42% Session close to close

+32.5% Peak Tracked

$356.99M Market Cap

0.1x Rel. Volume

In the Apr 21 session, AFJK gained 1.42%, reflecting a mild positive market reaction. Argus tracked a peak move of +32.5% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement flagged that AFJK fell out of compliance with Nasdaq reporting rules by missing it...

Analysis

This announcement flagged that AFJK fell out of compliance with Nasdaq reporting rules by missing its Form 10-K deadline for the year ended December 31, 2025. The company now faces a defined 60-day window to file the report or submit a remediation plan, with up to 180 days total to regain compliance. Investors may track progress on the delayed 10-K, any updates on the Nasdaq process, and how this interacts with the SPAC’s broader business combination timeline and going-concern risks disclosed in prior SEC filings.

Key Figures

10-K fiscal year end: December 31, 2025 10-K due date: March 31, 2026 Form 12b-25 filing date: April 1, 2026 +3 more

6 metrics

10-K fiscal year end December 31, 2025 Annual Report on Form 10-K period end

10-K due date March 31, 2026 Original SEC filing deadline for Annual Report

Form 12b-25 filing date April 1, 2026 Notification of Late Filing submitted to SEC

Nasdaq notice date April 17, 2026 Date Nasdaq issued deficiency notice

Initial cure period 60 calendar days Time from Notice to file 10-K or submit compliance plan

Maximum cure window 180 calendar days Potential total time from 10-K due date to regain compliance

Key Terms

form 10-k, nasdaq listing rule 5250(c)(1), form 12b-25, u.s. securities and exchange commission

4 terms

form 10-k regulatory

"its Annual Report on Form 10-K for the fiscal year ended December 31, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

nasdaq listing rule 5250(c)(1) regulatory

"not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1)"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

form 12b-25 regulatory

"the Company filed a Notification of Late Filing on Form 12b-25 with the SEC on April 1, 2026"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

u.s. securities and exchange commission regulatory

"with the U.S. Securities and Exchange Commission (the “SEC”)"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New York, NY, April 21, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on April 17, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Annual Report was due on March 31, 2026, and the Company filed a Notification of Late Filing on Form 12b-25 with the SEC on April 1, 2026.

The Notice has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company’s securities will be subject to delisting from Nasdaq.

Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Annual Report or submit a plan to Nasdaq to regain compliance with Nasdaq’s listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Annual Report’s due date to regain compliance. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

The Company is working diligently to complete and file the Annual Report and expects to regain compliance with the Listing Rule.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Aimei Health Technology Co., Ltd

Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the federal securities laws. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For investor and media inquiries, please contact:

Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022
Attention: Junheng Xie
Email: Xiejunheng@aimeihealth.com

FAQ

What did AFJK announce about receiving a Nasdaq notice on April 17, 2026?

AFJK said it received a Nasdaq notice for a delayed 2025 Form 10-K filing. According to the company, the Annual Report was due March 31, 2026 and a Form 12b-25 was filed April 1, 2026.

How long does AFJK have to regain compliance with Nasdaq after the April 17, 2026 notice?

AFJK has 60 calendar days to file the 10-K or submit a compliance plan. According to the company, an accepted plan can extend the cure period up to 180 calendar days from the original due date.

Does the Nasdaq notice affect AFJK's trading status immediately?

No, the notice has no immediate effect on listing or trading. According to the company, trading remains active while the company works to file the Annual Report and regain compliance.

What happens if Nasdaq does not accept AFJK's plan to regain compliance?

If Nasdaq rejects the plan, AFJK may appeal to a Nasdaq hearings panel. According to the company, the appeal opportunity exists but failure to regain compliance could lead to delisting proceedings.

What did AFJK file with the SEC after missing the March 31, 2026 deadline?

AFJK filed a Notification of Late Filing on Form 12b-25 on April 1, 2026. According to the company, this notified regulators of the delay while the company completes the Annual Report.